Related Experiment Videos
Coronary stenting with AVE microstents in acute myocardial infarction
R Ilia1, J M Weinstein, A Abu-Ful
1Cardiology Division, Soroka Medical Center, and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.
Insights
Coronary angioplasty for acute myocardial infarction (AMI) patients sometimes requires stent implantation due to dissection or recoil. Follow-up showed no reocclusion, death, or ischemia, indicating positive outcomes.
Area of Science:
- Interventional Cardiology
- Cardiovascular Medicine
- Acute Myocardial Infarction Research
Background:
- Acute myocardial infarction (AMI) poses significant risks.
- Coronary angioplasty is a key intervention for AMI.
- Stent implantation is sometimes necessary during angioplasty.
Purpose of the Study:
- To evaluate the need for stent implantation in AMI patients undergoing direct or rescue coronary angioplasty.
- To assess the safety and efficacy of stent use in this patient cohort.
Main Methods:
- Retrospective analysis of 36 AMI patients.
- Direct or rescue coronary angioplasty procedures.
- Stent implantation criteria: severe dissection or elastic recoil.
Main Results:
- 11 out of 36 patients (31%) required stent implantation.
- Reasons for stenting: 7 for severe dissection, 4 for elastic recoil.
- No instances of reocclusion, death, reinfarction, or ischemia during follow-up (up to 15 months).
Conclusions:
- Stent implantation is required in a significant minority of AMI patients undergoing angioplasty.
- Stenting for dissection or recoil in AMI is safe and effective.
- Positive clinical outcomes and absence of ischemic events suggest successful management.
Abstract:
Of 36 patients with acute myocardial infarction (AMI) who were referred for direct or rescue coronary angioplasty, 11 (31%) needed stent implantation. In 7 of them, the stent was implanted because of severe dissection and in 4, because of elastic recoil. All patients were discharged without clinical or electrocardiographic signs of reocclusion. No death, reinfarction or clinical evidence of ischemia occurred during up to 15 months of follow-up.